Wockhardt shares in focus after announcing an exit from loss-making US generics business
Published on 14/07/2025 07:33 AM
Wockhardt shares in focus after announcing an exit from loss-making US generics businessA strategic review concluded that the generics segment was misaligned with Wockhardt's innovation agenda.By Ekta Batra July 14, 2025, 7:33:17 AM IST (Published)1 Min ReadShares of Wockhardt Ltd. are in focus on Monday, July 14, after the company exited its US generics business, as part of a broader realignment.
The move aligns with the company's long-term vision to become a differentiated, innovation-led pharma company.
Wockhardt's focus will now shift to two pillars — new antibiotic drug discovery and biologics portfolio in insulin.
Wockardt's US generics business has been loss-making for several years. In the financial year 2025, US generics posted a loss of $8 million. A strategic review concluded that the generics segment was misaligned with Wockhardt's innovation agenda.
The company has filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code.
This affects two of its wholly-owned US subsidiaries — Morton Grove Pharma and Wockhardt USA LLC. Effective from July 11, 2025, the move enables a clean, structured exit from the US generics space.
The exit has freed up capital and management bandwidth for innovation-led segments.
Wockhardt shares ended the previous session 3.5% up at ₹1,756 apiece. The stock has gained 20.6% this year, so far.
Also Read: Paytm's retail shareholding declines for the fifth straight quarter even as MFs continue to buyContinue ReadingCheck out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!Tagsshare market todayWockhardtWockhardt share price